Skip to main content
Premium Trial:

Request an Annual Quote

Not So Much 'R' and Not So Much 'D'

At The New York Times Prescriptions blog, Duff Wilson says that outside business deals are keeping the pipelines of the major drug companies healthy, instead of internal research projects. According to a recent analysis from Fitch Ratings, the major drug makers are on pace to meet last year's level of 21 new drugs approved in the United States and Europe, but only thanks to acquisition and licensing deals. At the same time, 15 possible new drugs have had major problems, mostly with unfavorable results from clinical trials, Wilson says. Companies are, in fact, slashing spending on R&D, most notably Pfizer, which announced it's cutting its research budget by as much as $2.9 billion in the next two years. "In another analyst report with a broad view of the industry recently, Dr. Timothy Anderson of Bernstein Research looked at the prospects for nine major pharmaceutical companies to 2020," Wilson says. "His June 16 investor note found some companies with good long-term prospects from existing products, while others fall off the 'patent cliff' as generic competition is expected to pound their sales."

The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.